This study is for people with active Systemic Lupus Erythematosus (SLE), a disease where the immune system attacks the body. It sometimes affects the kidneys, called lupus nephritis (LN). The research is testing a new treatment, CABA-201, to see if it's safe and works well. People in the study will get a single dose of CABA-201 after taking two other medicines, cyclophosphamide (CY) and fludarabine (FLU). The study involves two groups: one with kidney problems and one without.
- Participants must be 18-65 years old with active SLE.
- Exclusions include severe reactions to certain medicines or existing severe diseases.
- People in the study cannot have had certain organ transplants or some past treatments.
How understandable was the trial content above?
Hard to understand
Easy to understand